Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 101 - 150 out of 16,993

Document Document Title
WO/2014/039916A1
Antisense polynucleotides and their use in pharmaceutical compositions to induce exon skipping in targeted exons of the gamma sarcoglycan gene are provided, along with methods of preventing or treating dystrophic diseases such as Limb-Gi...  
WO/2014/039920A1
Methods and kits for treating or reducing the likelihood of neurotoxin-induced respiratory failure in a subject, such as a victim of neurotoxic envenomation are provided. Also provided are methods for treating or reducing the likelihood ...  
WO/2014/040077A1
Disclosed herein are α7β1 integrin modulatory agents and methods of using such to treat conditions associated with decreased α7β1 integrin expression or activity, including muscular dystrophy. In one example, methods for treating a s...  
WO/2014/033654A1
The present invention provides a compound of formula (I) in acetate salt form (I) a method for manufacturing the compound of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacological...  
WO/2014/034756A1
The present invention relates to the provision of a pharmaceutical composition for use in the treatment of status epilepticus or a method for treating status epilepticus. The present invention provides a pharmaceutical composition for us...  
WO/2014/030624A1
Disclosed are: a therapeutic agent for myotonic dystrophy, particularly myotonic dystrophy associated with impaired glucose tolerance or diabetes; and a therapeutic agent for impaired glucose tolerance or diabetes each associated with my...  
WO/2014/030514A1
The present invention addresses the problem of providing a muscle atrophy inhibitor that is efficacious for disuse muscle atrophy and age-related muscle atrophy and easy to use. The muscle atrophy inhibitor comprises, as an active ingred...  
WO/2014/026330A1
The present invention relates to compounds according to Formula (I) or a pharmaceutically acceptable salt or solvate thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.  
WO/2014/028025A1
Disclosed is a compound for treatment of Myotonic Dystrophy type 1 having the formula (I) wherein X is selected from the group consisting of O, N, C, or S, Y is a homo- or heteroatomic 5-membered ring comprising one or more atoms selecte...  
WO/2014/028459A1
The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combina...  
WO/2014/026372A1
Disclosed is a pharmaceutical composition for inhibiting autophagy of motor neurons containing an effective amount of an active ingredient. The active ingredient is selected from the following groups: a compound of formula (I), pharmaceu...  
WO/2014/026140A1
Disclosed herein are methods for diagnosing, prognosing and treating muscular dystrophy. Also disclosed are methods of determining the effectiveness of an agent for the treatment of muscular dystrophy. Provided are methods of enhancing m...  
WO/2014/024984A1
The purpose of the present invention is to provide a hydrogen mixed gas supply device capable of administering a mixed gas having the hydrogen gas concentration and the oxygen gas concentration thereof each appropriately adjusted in acco...  
WO/2014/023007A1
Provided is a synthetic peptide derived from PEDF, which has 20-39 amino acid residues. Also provided are pharmaceutical compositions containing the synthetic peptide and the use thereof. The peptide is useful in promoting muscle or tend...  
WO/2014/019855A1
The present invention concerns a method for preparing a creatine fatty ester or derivative thereof comprising at least one step consisting in reacting a diprotected creatinine with a molecule bearing at least one alcohol functional group...  
WO/2014/016417A1
The present invention relates to HMGB1 variants that maintain HMGB1 wild type chemoattractant function while displaying abolished cytokine and/or chemokine stimulating properties. Such molecules are useful in therapy.  
WO/2014/016837A1
Compositions and methods utilizing thiol-containing short peptides having the sequence Cys-Lys-Met-Cys (SEQ ID NO: 1) and optionally N- and C- terminal modifications are provided, for increasing carnitine level in muscle tissues, and tre...  
WO/2014/015523A1
The invention relates to novel heteroaryl and heterocycle compounds and pharmaceutical compositions comprising them, uses and methods thereof for inhibiting the activity of PI3k and for treating inflammatory and autoimmune disorders dise...  
WO/2014/009738A3
The invention provides a compound capable of inhibiting ubiquitination for use in treating a disorder or symptom associated with reduced dystroglycan function in a subject.  
WO/2014/012050A3
Disclosed herein are compositions and methods for treatment of spinal muscular atrophy (SMA). In certain embodiments, compounds are provided that increase full-length survival of motor neuron (SMN) protein production by an SMN2 gene.  
WO/2014/007620A3
The invention relates to an oligonucleotide and to a pharmaceutical composition comprising said oligonucleotide. This oligonucleotide is able to bind to a region of a first exon from a dystrophin pre-mRNA and to a region of a second exon...  
WO/2014/004647A1
Nutritional products, compositions, functional ingredients, medical foods, pharmaceutical preparations and methods of use are disclosed for support and improvement of athletic performance (strength, flexibility, endurance, balance, and c...  
WO/2014/004470A1
Provided herein are methods, kits, and pharmaceutical compositions that include a PI3 kinase inhibitor for treating lupus, a fibrotic condition, or inflammatory myopathies and other conditions (e.g., skin conditions).  
WO/2014/003154A1
An NO production-enhancing agent, which comprises citrulline or a salt thereof and serine or a salt thereof as active ingredients; an agent for preventing the deterioration in a vascular endothelial function or improving the vascular end...  
WO/2014/001314A1
The present invention relates to combinations of phosphodiesterase 2 (PDE2) inhibitors with inhibitors of phosphodiesterase 10 (PDE 10). In particular, the invention relates to combinations of 1-aryl-4- methyl-[1,2,4]triazolo[4,3-a]-quin...  
WO/2014/000032A1
The present invention relates to phenyl amino pyrimidine bicyclic compounds formula (I) which are inhibitors of protein kinases including JAK kinases. In particular the compounds are active against JAK1, JAK2, JAK3 and TYK2 kinases. The ...  
WO/2013/189241A1
A pyrimidine diamine derivative as represented by formula (I), pharmaceutical salts thereof, pharmaceutical compositions containing the derivative, a preparation method therefor, and pharmaceutical uses thereof. The compound and the phar...  
WO/2013/187727A1
The present invention relates to novel phenylalkyl sulfamate compounds, a method for preventing or treating a disease associated with muscle spasm. The present invention ensures the enhancement of muscle relaxation activity essential for...  
WO/2013/183747A1
Provided is a material which can convert a skeleton muscle into a slow-fiber-type one and can improve or recover muscle mass or endurance. An agent for converting a skeleton muscle into a slow-fiber-type one, which comprises ginger or a ...  
WO/2013/181084A1
The present invention is directed to pharmaceutical compositions comprising antispasmodic C4-C8aliphatic-l,2-diols and C4-C8aliphatic-l,2,3-triols and their use to relieve the spasms associated with pain. These agents may be administered...  
WO/2013/180271A1
Provided are a fluorine-containing amino acid prodrug represented by general formula (I) that makes a fluorine-containing amino acid which is a group 2 metabotropic glutamate receptor agonist into a prodrug, or a pharmacologically accept...  
WO/2013/177176A1
Provided herein are methods of inducing differentiation of a mammalian myoblast into a mammalian myocyte that include contacting a mammalian myoblast with an oligonucleotide that decreases Mitogen-activated protein kinase kinase kinase k...  
WO/2013/177458A1
Phosphatidic acid, lyso-phosphatidic acid, and/or phospholipase D can be administered to exercising mammals to increase muscle mass and strength. These actives can be administered orally to aging, bedridden or cachectic patients, as well...  
WO/2013/175266A1
Phosphatidic acid is administered orally to increase muscle mass and strength in exercising mammals. Phosphatidic acid is administered orally to aging, bedridden or cachectic patients to improve nitrogen balance. The preferred form of ph...  
WO/2013/175386A1
Phosphatidic acid, lyso-phosphatidic acid, glycerol-3-phosphate and/or phospholipase D can be administered to exercising mammals to increase muscle mass and strength. These actives can be administered orally to aging, bedridden or cachec...  
WO/2013/177428A1
The present disclosure provides methods for increasing muscle contractility in a myotubular myopathy subject following administration of fewer than 20 doses of a chimeric polypeptide that has a myotubularin protein and an internalizing m...  
WO/2013/172681A1
The present invention relates to a pharmaceutical composition containing Kaempferia parviflora Wall. Ex. Baker extracts for treating muscle diseases, and more specifically to a pharmaceutical composition containing, as an active ingredie...  
WO/2013/173506A3
A method for treating muscular deterioration is disclosed. Also disclosed are embodiments of a compound, and compositions comprising the compound, for inhibiting muscular deterioriation, including atrophy, dystrophy, and cachexia, such a...  
WO/2013/170970A1
The invention relates to a pharmaceutical composition comprising a first pharmacologically active ingredient, which is selected from (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-sp iro[cyclohexane-1,1 '-pyrano[3,4,b]indol]-4...  
WO/2013/173506A2
A method for treating muscular deterioration is disclosed. Also disclosed are embodiments of a compound, and compositions comprising the compound, for inhibiting muscular deterioriation, including atrophy, dystrophy, and cachexia, such a...  
WO/2013/170385A1
It is described pharmaceutical compositions and methods for the treatment of viral infections, hypercholesterolemia, hypertriglyceridemia, Alzheimer's disease, prion disease and Duchene's muscular dystrophy with oligonucleotide chelate c...  
WO/2013/166557A1
The invention provides a method for treating cachexia, weakness, fatigue, and/or fever in a subject, the method comprising administering to the subject an effective amount of angiogenin or an angiogenin agonist. The method is particularl...  
WO/2013/170189A1
Methods of improving muscle energetics, muscle blood flow, and muscle health in humans, and specifically in adults and older adults, use nutritional compositions including a combination of beta-hydroxy-beta-methylbutyrate and beta-alanin...  
WO/2013/155330A1
Compositions and methods for identifying new treatments for Facioscapulohumeral muscular dystrophy (FSHD), and uses thereof.  
WO/2013/150153A1
Ketone bodies and ketone body esters maintain or improve muscle power output upon oral administration. Certain esters of hydroxybutyrate monomers are organoleptically acceptable and have high levels of uptake from the gut to the blood th...  
WO/2013/147072A1
The present invention is a cocrystal of 3-(15-hydroxypentadecyl)-2,4,4-trimethyl-2-cyclohexen-1-one and a C14-17 fatty acid.  
WO/2013/140787A1
The present invention addresses the problem of providing a novel preventive or therapeutic agent to prevent/treat idiopathic inflammatory myopathy effectively and safely. An antibody or an antibody fragment which specifically binds to DN...  
WO/2013/141202A1
Provided are a method for treating muscle atrophy, and a method and means for promoting muscle hypertrophy. The present invention provides a muscle-building agent characterized by comprising a TRPV1 agonist as an active component; as wel...  
WO/2013/137832A1
The invention relates to myostatin inhibitors, and in particular, to myostatin inhibitors comprising small molecules, and pharmaceutical compositions comprising the myostatin inhibitors. The invention also relates to methods for treating...  
WO/2013/135928A1
The present invention relates to the use of obestatin, or to the nucleotide sequence that codes for same, as an in vitro myogenic agent, and for the production of a drug for muscle regeneration, preferably for musculoskeletal regeneratio...  

Matches 101 - 150 out of 16,993